Aromatase inhibitor use is a risk factor of carotid plaque presence in endocrine-responsive breast cancer patients.

ABSTRACT:

Background/aims

The aromatase inhibitors (AIs) are well known anti-hormonal therapy in endocrine-responsive breast cancer patients. It can lead to dyslipidemia and be the risk factor of cardiovascular disease due to low estrogen level. However, some recent studies comparing AIs with placebo have shown controversial results. The aim of this study was to investigate lipid profiles, measurement of carotid intima-media thickness (IMT) and the presence of plaque among endocrine-responsive breast cancer treated with AIs compared to ones that were not treated with AIs.

Methods

A total of 85 postmenopausal women, who underwent breast cancer surgery during the age of 50 to 64 without history of statin use were included. There were 42 patients who were treated with AIs over 1 year (gr

SUBMITTER: Seo DH 

PROVIDER: S-EPMC6506747 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature